Caladrius Biosciences Inc. Daily Stock Analysis

Daily Stock Analysis, CLBS, Caladrius Biosciences Inc, priceseries

Caladrius Biosciences Inc. Daily Stock Analysis
Stock Information
Open
0.71
Close
0.68
High
0.71
Low
0.67
Previous Close
0.70
Daily Price Gain
-0.02
YTD High
1.14
YTD High Date
Jan 5, 2022
YTD Low
0.65
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.21
YTD Gain
-24.16%
52 Week High
2.25
52 Week High Date
Mar 10, 2021
52 Week Low
0.65
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-1.16
52 Week Gain
-63.11%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 24. 2017
3.67
Feb 16. 2017
5.19
17 Trading Days
41.55%
Link
LONG
Nov 16. 2017
3.07
Dec 4. 2017
3.34
11 Trading Days
8.75%
Link
LONG
Dec 28. 2017
3.49
Feb 1. 2018
4.11
23 Trading Days
17.74%
Link
LONG
Feb 21. 2018
4.04
Mar 5. 2018
4.37
8 Trading Days
8.13%
Link
LONG
Jan 2. 2019
4.08
Jan 22. 2019
4.81
13 Trading Days
17.96%
Link
LONG
Jan 8. 2020
2.83
Jan 17. 2020
3.12
7 Trading Days
10.17%
Link
LONG
Apr 3. 2020
1.76
Apr 23. 2020
2.10
13 Trading Days
19.29%
Link
LONG
May 11. 2020
2.05
May 14. 2020
2.27
3 Trading Days
10.98%
Link
LONG
Jul 13. 2020
2.16
Jul 23. 2020
2.47
8 Trading Days
14.44%
Link
LONG
Jan 19. 2021
1.63
Jan 27. 2021
2.04
6 Trading Days
24.93%
Link
Company Information
Stock Symbol
CLBS
Exchange
NasdaqCM
Company URL
http://www.caladrius.com
Company Phone
908-842-0100
CEO
David J. Mazzo
Headquarters
New Jersey
Business Address
110 ALLEN ROAD, SECOND FLOOR, BASKING RIDGE, NJ 07920
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000320017
About

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.

Description

Caladrius Biosciences, Inc. provides development and manufacturing services to the cell therapy industry in the United States. The company offers process development and clinical manufacturing services for therapeutic candidates in various stages of development. It is also developing CLBS03, a T regulatory cell clinical Phase II therapy targeting adolescents with type 1 diabetes. Caladrius Biosciences, Inc. has a strategic collaboration with Hitachi Chemical Co. America, Ltd. and Hitachi Chemical Co., Ltd. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading